US 11191818
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
granted A61KA61K38/4886A61P
Quick answer
US patent 11191818 (Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome) held by Takeda Pharmaceutical Company Limited expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 45
- CPC classes
- A61K, A61K38/4886, A61P, A61P11/00, A61P25/04